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INTRODUCTION 
On July 17, 2006, the Foundation for Taxpayer and Consumer 
Rights (FTCR) filed a request for reexamination of the three stem cell 
patents owned by the Wisconsin Alumni Research Foundation (WARF) 
through the Public Patent Foundation.  The consumer groups argue that 
the patents hinder the progression of research.2  The United States 
Patent and Trademark Office (USPTO) granted the request in 
September 2006.  Such reexamination could result in narrowing or 
canceling of some or all of the claims.  This Comment will outline why 
the USPTO should not invalidate or significantly narrow the patents.  
Specifically, this Comment will explain that the patents should remain 
valid.  First, this Comment will outline what stem cells are and what the 
patents at issue cover.  This Comment will then briefly explain the 
applicable law and policy considerations.  Finally, this Comment 
discusses why the patents should withstand their current challenge. 
I.  WHAT ARE STEM CELLS? 
There is no single definition of what a stem cell is or what its 
characteristics are.3  However, there are a number of properties the 
scientific community agrees upon being innate to stem cells.  Stem cells 
are undifferentiated precursor cells to other cells of the body.4  They 
have the ability to propagate themselves, through proliferation, 
essentially indefinitely without loosing their undifferentiated character.5  
This key characteristic significantly distinguishes stem cells from somatic 
cells.6  Somatic cells undergo only a finite number of replications in 
culture because of a sequential shortening of the chromosome ends 
(telomeres) during each cell division.7  Stem cells, in contrast to human 
somatic cells, express a protein (telomerase) that permits for the 
2. Andrew Pollack, Agency Agrees to Review Human Stem Cell Patents, N.Y. TIMES, 
Oct. 4, 2006, at C3. 
3. See The National Institute of Health Resource for Stem Cell Research, Stem Cell 
Basics (2006), available at http://stemcells.nih.gov/info/basics/defaultpage.asp. 
  4.   Id.  
  5.  Kevin A. D’Amour & Fred H Gage, Genetic and Functional Differences Between 
Multipotent Neural and Pluripotent Embryonic Stem Cells, 100 PROC. NAT’L. ACAD. SCI. U.S. 
11866 (2003).   
6. Somatic cells are all body cells that are not stem cells or reproductive cells.  
Wikipedia, Somatic Cell (May 28, 2007), http://en.wikipedia.org/wiki/Somatic_cells. 
7. Richard J. Hodes, Telomere Length, Aging, and Somatic Cell Turnover, 190 J. EXP. 
MED. 153, 153 (1999). 
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maintenance of chromosome ends and thereby allows for indefinite 
replication.8
Embryonic stem cells (ES cells) retain the ability to form “all three 
embryonic germ layers even after prolonged culture.”9  Adult stem cells, 
those that are found in an individual’s tissues, are typically limited in 
their ability to differentiate into only those cells inherent to the tissue in 
which they reside.10  For example, adult stem cells in the brain (neural 
stem cells) can differentiate into nerve cells, astrocytes, and 
oligoddendrocytes, all of which reside in brain tissue.11  However, adult 
stem cells that can differentiate into cells of tissues other than the one in 
which they reside have been isolated and are currently under 
investigation.12
The great hope for ES cells rests in their use as replacements for 
human tissues and organs that failed as a result of accidents, disease, or 
age.13  For example, scientists speculate that ES cells could alleviate or 
cure the insulin insufficiency in individuals suffering from diabetes.14  If 
the ES cells could integrate into the pancreatic islets and become 
insulin-producing cells, they would effectively ameliorate or even 
completely cure the diseased phenotype.15  Similar hope exists in the 
field of degenerative disorders, such as Alzheimer’s and Parkinson’s 
diseases.16  In addition, stem cells are important study objects to discern 
the human developmental process as well as biological processes.17  
8. James A. Thomson et al., Embryonic Stem Cell Lines Derived from Human 
Blastocysts, 282 SCIENCE 1145, 1145 (1998). 
9. Id. at 1146. 
 10.   The National Institute of Health Resource for Stem Cell Research, What are Adult 
Stem Cells? (2006), http://stemcells.nih.gov/info/basics/basics4.asp. 
11. Id. 
12. See, e.g., R. W. Mays et al., Development of Adult Pluripotent Stem Cell Therapies 
for Ischemic Injury and Disease, EXPERT OPIN. BIOL. THER. 7(2):173 (2007).  See also The 
National Institute of Health Resource for Stem Cell Research, What are Adult Stem Cells?, 
supra note 10.  Yu et al., Induced PluripointStem Cell Lines Derived From Human Semantic  
Cells, SCIENCE, November 20, 2007, http://www.sciencemag.org/cgi/content/abstract/1151526.  
13. Junying Yu & James A Thomson, Chapter 1: Embryonic Stem Cells, in 
REGENERATIVE MEDICINE, 4, (D.H.H. Sede), 2006, available at http://stem 
cells.nih.gov/info/scireport/2006report.htm (Sept. 2, 2007) (follow “Chapter 1: Embryonic 
Stem Cells” hyperlink). 
14. Gretchen Vogel, Stem Cells: New Excitement, Persistent Questions, 290 SCIENCE 
1672, 1673 (2000). 
15. National Cancer Institute, What would you hope to achieve from human pluripotent 
stem cell research? (2000), http://stemcells.nih.gov/news/newsArchives/achieve.asp. 
16. Id. 
17. See White House Press Release, Fact Sheet: Embryonic Stem Cell Research (Aug. 
9, 2001), available at http://www.whitehouse.gov/news/releases/2001/08/20010809-1.html. 
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However, it is important to note that this technology is still in its infancy 
and its true value is unclear.18
Currently, federal funds are available only for work with defined, 
already-existing human embryonic stem cell lines, i.e. federal funding 
may not be used to generate or work with new human embryonic stem 
cell lines.19
II.  THE STEM CELL PATENTS 
A patent grants the “right to exclude others from making, using, 
offering for sale, or selling the invention.”20  The three stem cell patents 
that are being reexamined are U.S. Patent numbers 5,843,780 (“Primate 
embryonic stem cells,” “the ‘780 Patent”),21 6,200,806 (“Primate 
embryonic stem cells,” “the ‘806 Patent”),22 and 7,029,913 (“Primate 
Embryonic Stem Cells,” “the ‘913 Patent”).23  The ‘780 Patent issued in 
1998 and claims “purified preparation of primate embryonic stem 
cells.”24  The ‘806 Patent issued in 2001 and claims “purified preparation 
of pluripotent human embryonic stem cells.”25  The ‘913 Patent issued in 
2006 and claims “methods of obtaining human hematopoietic cells from 
human pluripotent embryonic stem cells using mammalian stromal 
cells.”26  All three patents list Dr. James Thomson as the inventor, are 
18. James A. Thomson, Embryonic Stem Cell Lines Derived from Human Blastocysts, 
282 SCIENCE 1145, 1145-47 (1998). 
19. Guidance for Investigators and Institutional Review Boards Regarding Research 
Involving Human Embryonic Stem Cells, Germ Cells and Stem Cell-Derived Test Articles 
(Mar. 19, 2002),  [hereinafter Guidance].  See also, Diane T. Duffy, Background and Legal 
Issues Related to Stem Cell Research, Congressional Research Service (2002); National 
Institute of Health Resource for Stem Cell Research, What are Adult Stem Cells?, supra note 
10.  “Research on existing human embryonic stem cell lines may be conducted with Federal 
support [only] if the cell lines meet the U.S. President’s criteria which he announced on 
August 9, 2001.”  OFFICE OF THE DIRECTOR, NIH, NOTICE OF CRITERIA FOR FEDERAL 
FUNDING OF RESEARCH ON EXISTING HUMAN EMBRYONIC STEM CELLS AND 
ESTABLISHMENT OF NIH HUMAN EMBRYONIC STEM CELL REGISTRY (2001), 
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-005.html [hereinafter NIH 
NOTICE]. 
20. 35 U.S.C. § 154 (2006 & Supp. 2004). 
21. Primate Embryonic Stem Cells, U.S. Patent No. 5,843,780 (filed Jan. 18, 1996) 
(issued Dec. 1, 1998) [hereinafter “‘780 Patent”]. 
22. Primate Embryonic Stem Cells, U.S. Patent No. 6,200,806 (filed Jun. 26, 1998) 
(issued Mar. 13, 2001) [hereinafter “‘806 Patent”]. 
23. Primate Embryonic Stem Cells, U.S. Patent No. 7,029,913 (filed Oct. 18, 2001) 
(issued Apr. 18, 2006) [hereinafter “‘913 Patent”]. 
24. See ‘780 Patent, supra note 21. 
25. See ‘806 Patent, supra note 22. 
26. See ‘913 Patent, supra note 23. 
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assigned to WARF, and are licensed to Geron Corporation.27  This 
California biotechnology company “has an exclusive license to the 
WARF patents for heart, pancreas and neural cells.”28  Geron had 
provided significant financial support for Dr. Thomson’s research.29
III.  REEXAMINATION 
“A patent shall be presumed valid.”30  To challenge the validity of a 
patent, any person can apply for reexamination with the USPTO.31  The 
grounds for which such reexamination may be requested are limited to 
new questions of patentability raised by prior art, i.e. a printed 
publication or patent.32  The requestor must make his request in writing 
and explain the relevance of the cited prior art with regard to every 
claim to be reexamined.  For such a reexamination request to be 
granted, the examiner has to find that the cited prior art raises “a 
substantial new question of patentability.”33  Prior art raises a 
substantial new question of patentability if “there is a substantial 
likelihood that a reasonable examiner would consider the prior art . . . 
important in deciding whether or not the claim is patentable.”34
While a patent owner could potentially lose his patent, a requestor 
has nothing to lose because the USPTO refunds a large portion of the 
reexamination application fee should the request for reexamination not 
be granted.35  Requestors cannot appeal the USPTO’s decision not to 
grant the request for reexamination.36
The Public Patent Foundation, on behalf of the FTCR, filed a 
27. ‘780 Patent, supra note 21; ‘806 Patent, supra note 22; ‘913 Patent, supra note 23. 
28. Alex Lash, Government Nixes Stem-Cell Patents, THE FOUNDATION FOR 
TAXPAYER AND CONSUMER RIGHTS (Apr. 4, 2007), available at http://www.con 
sumerwatchdog.org/healthcare/nw/?postId=7671. 
29. See id. 
30. 35 U.S.C. § 282 (2000 & Supp. 2004). 
31. 4 DONALD S. CHISUM, CHISUM ON PATENTS § 11.07 (2004). 
32. U.S. PATENT & TRADEMARK OFFICE, U.S.  DEP’T OF COMMERCE, MANUAL OF 
PATENT EXAMINING PROCEDURE § 2216 (8th ed. 2006) [hereinafter MPEP].  Under 35 
U.S.C. 304, the Office must determine whether “a substantial new question of patentability” 
affecting any claim of the patent has been raised.  37 C.F.R. 1.510(b)(1) requires that a 
request for ex parte reexamination include “a statement pointing out each substantial new 
question of patentability based on prior patents and printed publications.” Id. 
33. 35 U.S.C. § 303(a) (2006). 
34. MPEP § 2242 (2006). 
  35.  Id. at § 1.26(c) (2006).  
36. 35 U.S.C. § 303(c) (2006 & Supp. 2004). 
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request for reexamination of the three stem cell patents in July, 2006.37  
The FTCR cited five sources, only four of which were deemed by the 
USPTO to raise “a substantial new question of patentability.”38  The 
fact that the FTCR’s request for reexamination was granted is not 
unusual.  The USPTO grants between 90% (ex parte) and 98% (inter 
partes) of reexamination requests.39  The claims at issue were changed in 
some way in nearly two-thirds of the ex parte proceedings, but all claims 
were cancelled in only 10% of the proceedings.40  The challenged claims 
remained unaltered in more than one-fourth of the proceedings.  Since 
90% of all reexamination proceedings resulted in either modified or 
unaltered claims and only 10% in cancellation, the USPTO history 
makes it unlikely that the FCTR will prevail in its desired cancellation 
of the ‘780 Patent and the ‘806 Patent.  In contrast, for the ‘913 Patent, 
an inter partes proceeding was granted.  In inter partes proceedings, less 
than one-third of the claims remained unaltered or were modified, while 
over 70% were cancelled.41
On April 3, 2007, the USPTO issued a preliminary rejection of the 
stem cell patents due to obviousness.42  This is not unusual, however, 
and signifies only the first of many steps.43  In its response filed on May 
31, 2007, WARF refutes the USPTO’s preliminary rejection.44  Further 
proceedings are likely to take months, if not years. 
37. WARF Stem Cell Patents, Public Patent Foundation (2007), http://www.pub 
pat.org/warfstemcell.htm. 
38. 35 U.S.C. § 303(a) (2006). 
39. Joseph D. Cohen, What’s Really Happening in Inter Partes Reexamination, 87 J. 
PAT. & TRADEMARK OFF. SOC’Y 207, available at http://www.stoel.com/Files/InterPartes.pdf 
(last visited Sept. 20, 2007).  An ex parte reexamination “allows a challenger to initiate a 
review by producing prior art . . . but . . . excludes the challenger from further participation in 
the examination process.”  BLACK’S LAW DICTIONARY 1306 (8th ed. 2004). An inter partes 
reexamination “allows a challenger to initiate a review by producing prior art, to respond to a 
patentee's statements regarding the new prior art, to address the patentee's responses to any 
office actions, and to request a hearing.”  Id. 
40. See id. 
41. See id. 
42. Andrew Pollack, 3 Patents on Stem Cells are Revoked in Initial Review, N.Y. TIMES, 
Apr. 3, 2007, at C2. 
43. See 37 C.F.R. §§ 1.510-1.570 (2006); MPEP § 2201 (8th ed. 2006) (displaying 
flowcharts on reexamination). 
44. WARF, Wisconsin Alumni Research Foundation Defends Patents in Response to 
Initial U.S. Patent and Trademark Office Action, (May 31, 2007), http://www.warf.org/ 
news/news.jisp?news_id=212.  The response is available at http://www.warf.org/uploads/ 
media/WARF_Response_to_PTO_Action_without_exhibits.pdf. 
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IV.  SHOULD THE PATENTS REMAIN VALID? 
The WARF patents should remain valid because the prior art cited 
by the requestors does not render the inventions obvious.  Also, the 
patents should remain valid because they do not stifle but rather 
promote the progress of science by allowing access to those who want it 
for a reasonable fee (or no fee at all).  Finally, the patents should remain 
valid to foster investors’ confidence in investing in embryonic stem cell 
research so that such research can continue despite current restrictions 
on available federal funding. 
A.  Obviousness 
To be patentable, an invention must be novel and useful45 as well as 
nonobvious.46  “Nonobviousness . . . means that an invention must not 
have been obvious to one with ordinary skill in the art to which the 
subject matter of the invention pertains at the time of the invention and 
in the light of . . . the prior art.”47  In contrast to novelty, an invention 
can be obvious even in the absence of a single prior reference as long as 
all components are described in prior references and “some motivation 
or suggestion to combine the references is provided by the prior art 
taken as a whole.”48  It should be noted that this general standard of 
nonobviousness was recently rejected by the Supreme Court.49  It is not 
entirely clear yet how this decision will impact biotechnological 
inventions.  However, it is speculated that “the impact of the Supreme 
Court’s ruling may not be as profound on life-science patents.”50  This 
notion is supported by the fact that “[w]ith life science inventions, ‘we 
can extrapolate and guess, but until we conduct an experiment, we don’t 
know if it’s going to work.’”51
When dealing with biotechnological inventions, the standard for 
obviousness has been more difficult to define.  In 1995, Congress 
amended 35 U.S.C. § 103 with subsection (b) to include a provision 
specific to biotechnology.52  This subsection “has been interpreted as 
45. 35 U.S.C. §§ 101 and 102 (2006 & Supp. 2004). 
46. Id. § at 103(a). 
47. 2 DONALD S. CHISUM, CHISUM ON PATENTS § 5.01 (2004). 
48. Id. at § 5.04[1][e][ii] (citing In re Beattie, 974 F.2d 1309, 1312 (Fed. Cir. 1992)). 
49. KSR Int’l Co. v. Teleflex, Inc., 127 S. Ct. 1727 (2007). 
50. Joe Vanden Plas, Supreme Court Ruling Seen as Blow to WARF Stem Cell Patents, 
WISCONSIN TECHNOLOGY NETWORK (May 2, 2007), http://wistechnology.com/article. 
php?id=3889. 
51. Id. 
52. 35 U.S.C. § 103(b) (2006 & Supp. 2004). 
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requiring that the prior art lead to the production of the invention and 
that there be a reasonable expectation that the invention can be carried 
out successfully for the invention to fail the non-obvious requirement.”53
Robertson,54 Piedrahita,55 and Robertson,56 three of the cited prior 
art references in the application for reexamination, exclusively use and 
discuss animal models, mostly murine.57 There is no doubt that murine 
(1) Notwithstanding subsection (a), and upon timely election by the applicant for 
patent to proceed under this subsection, a biotechnological process using or 
resulting in a composition of matter that is novel under section 102 and nonobvious 
under subsection (a) of this section shall be considered nonobvious if-- 
 (A) claims to the process and the composition of matter are contained in 
either the same application for patent or in separate applications having the 
same effective filing date; and 
 (B) the composition of matter, and the process at the time it was invented, 
were owned by the same person or subject to an obligation of assignment to the 
same person. 
(2) A patent issued on a process under paragraph (1)-- 
 (A) shall also contain the claims to the composition of matter used in or 
made by that process, or 
 (B) shall, if such composition of matter is claimed in another patent, be set 
to expire on the same date as such other patent, notwithstanding section 154. 
(3) For purposes of paragraph (1), the term "biotechnological process" means-- 
 (A) a process of genetically altering or otherwise inducing a single- or 
multi-celled organism to-- 
     (i) express an exogenous nucleotide sequence, 
 (ii) inhibit, eliminate, augment, or alter expression of an endogenous 
nucleotide sequence, or 
 (iii) express a specific physiological characteristic not naturally 
associated with said organism; 
 (B) cell fusion procedures yielding a cell line that expresses a specific 
protein, such as a monoclonal antibody; and 
 (C) a method of using a product produced by a process defined by 
subparagraph (A) or (B), or a combination of subparagraphs (A) and (B). 
Id. 
53. Damon J. Whitaker, The Patentability of Embryonic Stem Cell Research Results, 13 
U. FLA. J.L. & PUB. POL’Y 361, 370 (2002). 
54. ELIZABETH J. ROBERTSON, Isolation, Properties, and Karyotype Analysis of 
Pluripotential (EK) Cell Lines from Normal and Parthenogenetic Embryos, in 
TERATOCARCINOMAS AND EMBRYONIC STEM CELLS:  A PRACTICAL APPROACH, 71-112 
(Elizabeth J. Robertson ed., IRL Press, Oxford 1987). 
55. J.A. Piedrahita et al., On the Isolation of embryonic Stem Cells: Comparative 
Behavior of Murine, Porcine and Ovine Embryos, 34 THERIOGENOLOGY 879 (1990). 
56. ELIZABETH J. ROBERTSON, Embryo-derived stem cell lines, in TERATO 
CARCINOMAS AND EMBRYONIC STEM CELLS; A PRACTICAL APPROACH, 71-112 (Elizabeth 
J. Robertson ed., IRL Press, Oxford 1987). 
57. The term “murine” is used by scientists to refer to a mouse, but includes all things 
“of or relating to a murid genus (Mus) or its subfamily (Murinae) which includes the common 
household rats and mice.”  MERRIAM-WEBSTER ONLINE DICTIONARY, http://www.m-
  
2008] REEXAMINING STEM CELL PATENTS  115 
 
 
embryonic stem cells have been isolated and cultured, at least to a 
certain extent, prior to the successful culture of human embryonic stem 
cells.  However, these previous experiments do not render the patented 
technology obvious. 
First, the vast majority of technologies designed for human 
applications have some form of animal test precursor.58  It is neither 
practical nor economical, let alone ethical, to conduct initial 
experimentations on humans.59  Therefore, virtually every experiment, 
trial, or treatment with human tissue had to begin with animal 
experimentation.  It would defeat the purpose of the patent system to 
allow for individuals that conduct the preliminary animal experiments to 
claim exclusive rights to any possible human applications without having 
had successfully translated the technology at issue to human tissue.  
Patents grant the right to exclude others from making and using an 
invention.60  Researchers should not be allowed to “call dibs” on a 
technology that was never successfully reduced to practice in humans 
merely because successful animal experimentation has been conducted.  
Neither should such animal experimentation render the human 
application obvious so as to make it unpatentable for any researcher 
who adapts the technology for human application.  This would 
discourage researchers from communicating possible alternative species 
applications of the technology to others.  Rather, it would encourage 
researchers to keep their animal data under a veil of secrecy to preclude 
the possibility of barring themselves from possible application to other 
species.  Secrecy is the very thing the patent system intends to 
discourage.61
Second, an obviousness rejection requires that the “prior art 
suggests to a person of ordinary skill in the art to make the claimed 
invention.”62  In other words, the prior art made it “obvious to try.”63  
w.com/dictionary/murine (last visited Sept. 30, 2007). 
58. See, e.g., 45 C.F.R. § 46 (2006). 
59. See, e.g., David J. Rothman, Ethics and Human Experimentation: Henry Beecher 
Revisited, 317 NEW ENG. J. MED. 1195 (1987); Joseph V. Brady & Albert R. Jonsen, The 
Evolution of Regulatory Influences on Research with Human Subjects, in HUMAN SUBJECTS 
RESEARCH – A HANDBOOK FOR INSTITUTIONAL REVIEW BOARDS (Robert A. Greenwald 
et al. eds., Plenum Press 1982). 
60. See 35 U.S.C. § 154(a)(1) (2006 & Supp. 2004); 35 U.S.C. § 271 (2006 & Supp. 
2004). 
61. See Gideon Parchomovsky, Publish or Perish, 98 MICH. L. REV. 926 (2000). 
62. DONALD S. CHISUM ET AL., PRINCIPLES OF PATENT LAW 617 (Foundation Press 
3rd ed. 2004). 
63. In re O’Farrell, 853 F.2d 894, 902 (Fed. Cir. 1988). 
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However, an invention that is obvious to try is not necessarily obvious 
under Section 103.64  A second requirement for an obviousness rejection 
under Section 103 is that there must be a “reasonable expectation of 
success.”65  This second requirement is important because otherwise 
everything that is obvious to try would be unpatentable.  In other words, 
while people may have thought of trying to make a given invention, 
nobody has the incentive to invest in actually going forward with the 
research because their investment cannot be returned in the absence of 
patent protection.  Such a view would clearly defeat the purpose of the 
patent system. 
Even if the FTCR could establish that there was a suggestion in the 
prior art to establish human stem cells, it lacks the second required 
showing, the expectation of success.  In fact, as discussed in the next 
paragraph, the prior art, if anything, teaches away from establishing 
human stem cells. 
Third, several promising technologies have not yet been tried on 
human subjects because the interspecies differences make initial success 
unlikely.66  This is especially true for experiments that have been 
conducted with the experimental animal most scientists work with, the 
mouse.  In the case of stem cells, “[h]uman and murine ESCs differ from 
each other in a wide spectrum of genes.”67  These differences affect 
growth rates, culture requirements, and marker expression.68  Most 
importantly, these differences affect pathways required to maintain the 
stem cell phenotype.69  Although the details and underlying mechanisms 
of those differences are only recently being elucidated, the fact that 
human cells are not identical to murine cells is evident because it took 
scientists almost a decade to replicate the murine experiments in human 
cells.70  The “derivation and manipulation of murine stem cells was an 
elite skill.”71  “[T]he manipulation of [human embryonic stem cells is] an 
even more highly skilled art and one that few scientists have yet 
64. See id. at 902-04. 
65. Id. at 904. 
66. See Gretchen Vogel, Four Genes Confer Embryonic Potential, 313 SCIENCE 27 
(2006). 
67. Chia Lin Wei et al., Transcriptome Profiling of Human and Murine ESCs Identifies 
Divergent Paths Required to Maintain the Stem Cell State, 23 STEM CELLS 166, 173 (2005). 
68. Id. at 167. 
69. Id. 
70. See, e.g., Wikipedia, Key E Stem Cell Research Events (Aug. 31, 2007), 
http://en.wikipedia.org/wiki/Stem_cell. 
71. Melissa Little, Wayne Hall, & Amy Orlandi, Delivering on the Promise of Human 
Stem-Cell Research, 7 EMBO REPORTS 1188, 1191 (2006). 
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mastered.”72
It is important to remember that this is not an area of science that 
was inactive and has only now become popular.  Quite the opposite is 
true; stem cell research is one of the “hottest” areas of scientific 
research because of its enormous potential to revolutionize the way 
medicine is practiced.73  In fact, scientists have desired success in this 
area so much that it has led some to falsify research results and pretend 
to have been successful.74
Even if a prima facie case of obviousness can be established, it can 
be rebutted by secondary considerations.75  In Graham v. John Deere 
Co., the Supreme Court enumerated such secondary considerations that 
can rebut a prima facie case of obviousness, which are (1) commercial 
success; (2) long-felt but unsolved need; and (3) failure of others.76
With regard to the WARF patent, all three considerations clearly 
weigh against obviousness.  The patented technology is commercially 
successful because the patents have resulted in a large number of 
licensing agreements as well as the formation of start-up companies.77  
There was a long-felt but unsolved need in the scientific arena to 
establish human embryonic stem (“hES”) cell cultures.  As mentioned 
above, even after successfully practiced with murine cells, it took several 
more years before human embryonic cell lines were established.78 
Finally, it is difficult to estimate how many other scientists have tried 
but failed to grow stable hES cells in vitro.  However, given the 
72. Id. 
73. The National Institute of Health Resource for Stem Cell Research, Frequently 
Asked Questions, http://stemcells.nih.gov/info/faqs.asp (last visited Sept. 2, 2007); Fiona M. 
Watt & Kevin Eggan, Molecular Mechanisms of Stem-Cell Identity and Fate, NATURE 
REVIEWS, available at http://www.nature.com/nrc/posters/stemcell/index.html (last visited 
Sept. 30, 2007). 
74. S Korea Scientist on Fraud Charge, BBC NEWS (May 12, 2006), 
http://news.bbc.co.uk/2/hi/asia-pacific/4763973.stm; Nathan Seppa, Stem Cell Controversy: 
Scientist is Retracting Landmark Finding, SCIENCE NEWS ONLINE (Dec. 24, 2005), 
http://www.sciencenews.org/articles/20051224/fob7.asp. 
75. Graham v. John Deere Co., 383 U.S. 1, 18-19 (1966). 
76. Id. at 17. 
77. “WiCell has distributed cells to more than 360 research groups in 40 states and 24 
countries. . . .  [O]f all of the academic papers published in scientific journals between 2002 
and 2004, a full 67 percent used [the WARF] cells. . . .  Over the past year, the number of 
WARF commercial licenses has doubled, reflecting an increase in industry-supported 
research and development.”  Wisconsin Alumni Research Foundation Changes Stem Cell 
Policies to Encourage Greater Academic, Industry Collaboration, WARF NEWS, Jan. 23, 2007, 
http://www.warf.org/news/news.jsp?news_id=209. 
78. Wei et al., supra note 67, at 167. 
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enormous excitement and anticipation for hES cell research in the 
academic as well as industry settings, it can be presumed that numerous 
other scientific groups have unsuccessfully tried to achieve this goal.  
For example, Time Magazine described Dr. Thomson as “one of the 
people ‘who are changing the world’ and . . . Science . . . called his 
invention ‘one of the most significant milestones in the history of 
science.’”79  Further, Dr. Thomson has obtained countless awards and 
recognitions for his achievements in stem cell research.80  This portrayal 
of Dr. Thomson’s work by lay as well as scientific journals and 
institutions demonstrates that “‘at the time of the discoveries, leading 
scientist and scholars from around the world saw Thomson as the first 
scientist to isolate and proliferate human embryonic stem cells.’”81  
Therefore, even if a prima facie case of obviousness could be 
established, it could easily be rebutted with these secondary 
considerations.82
B.  The Validity of the Stem Cell Patents Is Consistent with the Purpose 
of Patent Law 
The constitutional objective of patents is to “promote the Progress 
of Science.”83
In other words, the purpose of the patent system is to provide 
incentives for invention and creation.84  However, science for science’s 
sake is rare these days.  Although most scientists do not conduct their 
research with a patent in mind, the organization for which the scientists 
79. Joe Vanden Plas, WARF Questions Relevancy of Documents Used to Uphold Patent 
Challenge, WISCONSIN TECHNOLOGY NETWORK (May 31, 2007), http://wisconsintech 
nology.com/printarticle.php?id=3965. 
80. See, e.g., University of Wisconsin-Madison Endocrinology-Reproductive 
Physiology Program Faculty Webpage for Dr. James Thomson, http://www.erp.wisc.edu/ 
faculty/thomson.html (last visited Sept. 9, 2007) (listing such awards as:  American Academy 
of Achievement Golden Plate Award (1999); World Technology Award Finalist, Health and 
Medicine, The Economist-London (1999); Man of the Year, Madison Magazine (2001); Hall 
of Fame Award for Scientific Achievement, 15th Annual Conference of Biotechnology CEOs 
(2001); Featured as "One of the most intriguing people of 2001," People Magazine (2001); 
Featured as one of eighteen scientists representing "America’s Best in Science and 
Medicine,” Time magazine (2001); Wilson S. Stone Memorial Award for Biomedical 
Research (2001); Lois Pope Award Annual LIFE International Research Award (2002)). 
81. Vanden Plas, supra note 79 (quoting WARF managing director). 
82. MPEP § 1504.03(III) (8th ed. 2006). 
83. U.S. CONST. art. I, § 8, cl. 8. 
84. See, e.g., Sinclair & Carroll Co., Inc. v. Interchemical Corp., 325 U.S. 327, 330-31 
(1945). 
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work probably does.85  Both universities and private companies have a 
vested interest in developing and protecting intellectual property; 86 
many funding sources look to the patent portfolio, or patenting 
potential, of such organizations before even considering making an 
investment.  Thus, from the organization’s point of view, the objective is 
not only for the scientist to conduct his or her research, but is also for 
investors to fund such research.  “Investors in any new technology are 
concerned to protect their investment.”87  Without the possibility of 
patent protection of a research product, investors would be far less 
likely to invest because the opportunities for financial return would be 
minimal.  In other words, the investors would carry the risk and would 
have marginal expectations of return. 
This is especially true for stem cell research.88  “Investors have . . . 
been reluctant to make . . . investments into [related research] for a 
number of good reasons.”89  Among those reasons is the concern 
whether future intellectual property protection is possible should useful 
results be obtained.90  “[R]isk aversion among potential investors is a 
real barrier to . . . this research.”91  Thus, solid patent protection of 
current and future technology is critical to the progress of science 
because it vitally depends on private investments, especially in the 
absence of federal funding. 
Society is gaining many things from the patent protection of an 
invention.  One of the most important is disclosure.  The tradeoff for 
obtaining this temporary monopoly is that the patent holder has to 
disclose the invention and enable someone with ordinary skill in that art 
to reproduce or use the invention.92
It is true that “unwarranted monopoly power must be vigilantly 
guarded against.”93
85. See, e.g., Stacey Higginbotham, How Open? That's the Big Patent Question, CNET 
News.com, Sept. 25, 2005, http://news.com.com/How+open+Thats+the+big+patent+question 
/2100-1014_3-5877028.html. 
86. See, e.g., Nathaniel Lipkus, How to Understand Product Development: Public-
Private Partnerships as Vehicles for Innovation in Combating Neglected Disease, 10 MICH. ST. 
J. MED. & LAW 385 (2006). 
87. Gareth Williams, Patenting of Stem Cells, 1 REGEN MED. 697 (2006). 
88. See Little, supra note 71, at 1191. 
89. Id. at 1190. 
90. Id. at 1191. 
91. Id. 
92. 35 U.S.C. § 112 (2006). 
93. Christopher D. Hazuka, Supporting the Work of Lesser Geniuses: An Argument for 
Removing Obstructions to Human Embryonic Stem Cell Research, 57 U. MIAMI L. REV. 157, 
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However, WARF is not in possession of such an unwarranted 
monopoly.  WARF permits scientists to use the invention during the 
patent’s lifetime with only a few restrictions.  One can hardly 
characterize WARF’s use of its patent as rendering the monopoly 
“unwarranted.”  It merely protects the investors’ capital that enabled 
the research culminating in these stem cells. 
Investment enables research.  This is especially true since no federal 
funding is currently available for the generation of new hES cell lines.94  
Any research in this area has to be funded through private investments.  
Private investment was what made Thomson’s research possible as well.  
The stem cell project would never have been able to go forward without 
Geron’s funding for the University of Wisconsin.  Geron would not have 
funded research that is purely academic with no prospect of financial 
return for the company.  In fact, such a decision would have been 
against the business purpose to maximize shareholder wealth.95  
Financial return can be secured only through the protection of a patent. 
It can hardly be true that the WARF patents stifle research.  Quite 
the opposite is true.  Scientific progress is accelerated because 
researchers can use the WARF ES cells, rather than having to establish 
their own ES cell lines.  Furthermore, the patents act as incentives for 
scientists to explore other avenues to design around the patents.  It is 
important to remember that WARF “did not contract for limitations on 
[California’s] ability to compete.”96  WARF “may compel rivals . . . to 
do more work to develop [alternatives] independently, but this 
promotes rather than restricts competition.”97  For example, promising 
research has come from the generation of pluri-potent cells from 
somatic (adult body) cells.98  In addition, StemCells, Inc. obtained a 
patent on generating human neural stem cell cultures from “embryonic . 
172 (2002). 
94. “Research on existing human embryonic stem cell lines may be conducted with 
Federal support [only] if the cell lines meet the U.S. President’s criteria which he announced 
on August 9, 2001.”  NIH NOTICE, supra note 19.  See also Duffy, supra note 19. 
95. Dodge v. Ford Motor Co., 170 N.W. 668, (684 Mich. 1919) (“A business 
corporation is organized and carried on primarily for the profit of the stockholder.”). 
96. Idx Sys. Corp. v. Epic Sys. Corp., 285 F.3d 581, 585 (7th Cir. 2002) (stating that 
non-disclosure agreements are not subject to the same restrictions as non-compete 
agreements). 
97. Id. 
  98.  Gretchen Vogel, Researchers Turn Skin Cells into Stem Cells, SCIENCENOW 
DAILYNEWS, November 20, 2007, http://sciencenow.sciencemag.org/cgi/content/full/2007/112 
0/1. 
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. . fetal, neonatal, and adult tissue.”99
Other human embryonic stem cell lines might be created via a 
different, perhaps better, method in the future.  Without the patent, 
there would be no need to invest research dollars into designing such 
new techniques.  Therefore, the patent acts as an incentive for future 
scientific research in the field of stem cell research.  “No one doubts this 
with physical property:  General Motors is entitled to control 100% of 
its own output of mufflers, without handing any of them over to Ford or 
Toyota or Volkswagen.”100
C.  Disclosure 
One of the goals of the patent system is “to motivate disclosure of 
inventions and reduce the use of trade secrets as a method of protecting 
intellectual property.”101  This is especially important for the biological 
sciences.  First, due to the high cost of conducting biomedical research, 
it is important not to use tax dollars to fund research that merely 
duplicates scientific research already conducted.  Only when findings 
are disclosed, not concealed, can such duplicative research be avoided. 
Second, the ability to disclose scientific findings is the life-blood of 
scientists. Publications in peer-reviewed journals and presentations at 
national or international meetings allow the scientist to share his or her 
result with the scientific community.  Thereby, the scientist does not 
only disseminate his knowledge to others but may get valuable feedback 
from other scientists, establish collaboration among institutions, and 
gain valuable recognition in his field of study.  Without publishing the 
results of his or her research, the scientist cannot establish a track 
record in the scientific community.  Without a track record, it will be 
challenging for the scientist to obtain funding for future research 
undertakings.  Thus, disclosing his research results serves many 
important functions that propel scientific research at large.  However, 
scientists that make disclosures without the protection of a patent may 
find themselves barred from continuing with their research because 
someone else “scooped” them.102  Publications are typically reviewed for 
99. Posting of Douglas Sorocco to Phosita | An Intellectual Property Law Blog!, US 
Stem Cell Patent Issued, http://www.okpatents.com/phosita/archives/2004/08/us_stem_cell_pa 
.html (Aug. 23, 2004, 12:44 CST). 
100. Idx Sys. Corp., 285 F.3d at 585. 
101. David J. Weitz, The Biological Deposit Requirement: A Means of Assuring 
Adequate Disclosure, 8 HIGH TECH L.J. 275, 298 (1993). 
102. A patent provides the “right to exclude others from making, using, offering for 
sale, or selling the invention.”  35 U.S.C. § 154(a)(1) (2006).  Should an inventor disclose his 
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novelty.  Thus, if someone else has published the same results 
elsewhere, the editors of another journal are unlikely to accept an 
article with the same results. 
Grants of patents are useful not only to the owner but also to the 
public, especially with regard to break-through scientific findings in the 
biosciences.  This is due to the fact that, in the special case of biological 
material, a patentee may be required to make a deposit with the PTO.103  
Such a deposit is available for public inspection.104  Because it is often 
impossible for other researchers to reproduce a biotechnological 
invention, the interest of the pertinent scientific community is 
safeguarded through a patent on the invention.105  The patentee “has a 
strong economic incentive” to keep his biological material inaccessible 
to the public.106  A patent, however, allows for the researcher to share 
his findings safely with the public. 
D.  Not Research but Profit-Making Is Limited by the Patents 
The Patents, especially ‘806, are quite broad and may therefore be 
vulnerable.  Nevertheless, the USPTO should not invalidate the patents.  
It is clear what the patents would not cover, i.e., the generation of stem 
cells from somatic tissue or by nuclear transfer.  Experiments 
attempting this task are currently underway.107  The patents do not 
describe the one and only method to generate stem cells and maintain 
the desired embryonic phenotype and genotype in vitro. 
Experimentation for new methodology is currently only possible 
through private funding frustrating academic scientists.  However, 
academic scientists do not need to generate other cell lines because they 
can use the patented cell lines for a minimal fee.108  It should be noted 
that “WARF imposes no restrictions on patenting or publishing the 
results of basic academic research.”109  Research itself is thus not stifled.  
invention without this protection, other companies or individuals are free to duplicate and 
practice the invention. 
103. See 37 C.F.R. §§ 1.801-1.809 (2006); 37 C.F.R. § 1.93 (2006); MPEP Appendix R, 
Patent Rules § 1.93 (8th ed. 2006). 
104. 37 C.F.R. § 1.808(c) (2006). 
105. See Weitz, supra note 101. 
106. Id. at 299-300. 
107. See, e.g., Jeffrey M. Perkel, Life Science Technologies Stem Cells: Beyond Somatic 
Cell Nuclear Transfer, SCI. MAG., Apr. 4, 2007, available at http://www.sciencemag.org/prod 
ucts/lst_20070420.dtl. 
108. See infra Part V.G. 
109. Posting of Kevin E. Noonan to Patent Docs, It’s Time to Stop the Hypocrisy over  
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Rather, the licensing conditions limit the amount of commercial profit 
companies can make using the patented invention.  Limits imposed onto 
the ability of individuals or companies to profit from an invention that 
was patented by another can hardly be a reason for finding a patent 
invalid. 
E.  The Upstream Technology Argument 
Opponents of the WARF patents argue that the patents cover 
“upstream” technology.110  In other words, stem cells can be useful for 
making future biotechnological discoveries and inventions.  However, 
an “upstream-downstream” distinction can hardly be made in 
biotechnology because there is no workable line-drawing mechanism.  
Even if there was a method to distinguish what is and what is not 
upstream technology, it would hardly be reasonable to propose that 
upstream technology is generally unpatentable.  Upstream technology 
should especially be patentable because it includes all pioneer work.111
For most inventions, especially in biological sciences, the true 
significance is rarely clear.  For example, in the 1940s, two scientists 
studied a virus that infects bacteria.112  Perhaps some were wondering 
why it would be of any significance to study these bacteriophages.  Most 
certainly, the discovered methods and observations would not have 
been characterized as upstream technology.  Later, it became clear that 
the two scientists, Max Delbrück and Salvador Luria, had developed a 
simple model system for DNA transfer, the first cloning of genetic 
information.113  This simple example illustrates that characterizations of 
technological advancements as “upstream” or “not upstream” are 
hardly possible.  The potential for future scientific use rests in every 
scientific discovery.  Thus, essentially all technologies are “upstream” in 
some way.  One cannot punish an inventor by making his discovery 
unpatentable simply because his or her invention is highly useful. 
Stem Cell Patent – Part II, available at http://patentdocs.typepad.com/patent_docs/2007/04/its_ 
time_to_sto_1.html (Apr. 26, 2007). 
110. See, e.g., Amy Rachel Davis, Patented Embryonic Stem Cells: The Quintessential 
"Essential Facility"?, 94 GEO. L. J. 205 (2005). 
111. A pioneer work or invention refers to something entirely new rather than an 
improvement within an existing branch of science.  See James E. Rogan, Prepared Remarks 
at the Hearings on Competition and Intellectual Property Law and Policy in the Knowledge-
Based Economy (Feb. 6, 2002), available at http://www.uspto.gov/web/offices/com/comm 
06feb2002.html. 
112. S. E. Luria & M. Delbrück, Mutations of Bacteria from Virus Sensitivity to Virus 
Resistance, 28 GENETICS 491 (1943). 
113. Id. 
  
124  MARQUETTE INTELLECTUAL PROPERTY LAW REVIEW[Vol. 12:1 
 
 
Formerly, the government provided funding for “premarket or 
‘upstream’ research and encouraged broad dissemination of results in 
the public domain.”114  However, because the technology was freely 
available, commercial development was unattractive to investors.  To 
remedy this situation, Congress encouraged patenting of federally 
funded research results.115  Patent protection provided the needed 
economic incentive to encourage investors to support research as well as 
commercial development.116  Critics argue, however, that “[a] 
proliferation of intellectual property rights upstream may be stifling life-
saving innovations further downstream in the course of research and 
product development.”117  The obvious counterargument to this criticism 
is that upstream innovations would never be made without the 
expectation of financial returns.  “Scientific research is an expensive 
endeavor.”118  Funding for such research would be unavailable and 
“[c]ommercialization would be impossible if not for the temporary 
monopoly rights.”119
F.  WARF Is Not “Keeping It All to Itself” 
The FTCR argues that the patents should be invalid because of the 
danger that WARF will keep stem cell research to itself and thereby 
stifle the scientific progress.120  Nothing could be further from the truth.  
Science is rarely conducted in a vacuum.  In fact, the scientific 
community operates to support and inspire its constituents.  Therefore, 
it is not in WARF’s interest to keep the benefits of embryonic research 
to itself. 
WARF has not only shared the patent with over 400 scientists 
worldwide,121 but has also included training for a reasonable royalty or 
free of charge.122  Further, scientists at the NIH and FDA, as well as 
114. Michael A. Heller & Rebecca S. Eisenberg, Can Patents Deter Innovation? The 
Anitcommons in Biomedical Research, 280 SCIENCE 698, 698 (1998). 
115. See id. 
116. See id. 
117. Id. 
118. Diana A. Villamil, Redefining Utility in Determining the Patentability of DNA 
Sequences, 5 J. MARSHALL REV. INTELL. PROP. L. 238, 252 (2006). 
119. Id. 
  120.   John M. Simpson, Wisconsin Group Eases Stem Cell Patent Restrictions After 
FTCR – PubPat Challenge, January 23, 2007, http://www.pubpat.org/warfstemcelleased.htm.    
121. Elizabeth L.R. Donley, How Wisconsin Moved to the Front Line of Stem Cell 
Research, MILWAUKEE J. SENTINEL, Sept. 2, 2006, available at http://www.jsonline.com/ 
story/index.aspx?id=489946. 
  122.  See WiCell Research Institute – Technical  Classes, 
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scientists within the State of Wisconsin, are free to use the technology 
without paying any royalty.123  There are not many examples where the 
owner of a patent shares its protected invention as extensively as 
WARF does right now. 
It is also worth noting that the patented technology is not simply 
blocking others from practicing the technique.  Scientists at the 
University of Madison and at the WiCell Research Institute124 have been 
enormously prolific.  This productivity is reflected in successful 
competition for research grants, thirty-eight peer-reviewed publications, 
and over thirty patent applications.125  Using the patented stem cells, 
scientists have produced blood and plasma supplies, generated “insulin-
producing cells to develop new treatments for diabetes,” and were 
successful in restoring motor movement in several animal models by 
regenerating spinal cord tissue.126
Finally, WiCell is giving back to the public, which initially funded 
some of the research that resulted in the patented invention.  It is doing 
so not only through the furthering of research, as discussed above, but 
also through raising public awareness of stem cell technology.  
Specifically, “the institute already offers one- and three-day courses for 
journalists and teachers.”127  In a few months, WiCell will launch a 
“major public education initiative” to educate anyone interested in this 
important technology and its potential in improving the way medicine is 
practiced today.128  Thus, the WARF patents are most certainly not 
“stopping . . . domestic human ES cell research at its infancy.”129
http://www.wicell.org/index.php?option=com_content&task=blogsection&id=16&Itemid=149 
(last visited Jan. 11, 2008). 
123. The NIH signed a memorandum of understanding with WARF and its subsidiary 
WiCell.  See Press Release, National Institute of Health, National Institutes of Health and 
WiCell Research Institute, Inc., Sign Stem Cell Research Agreement (Sept. 5, 2001), available 
at http://www.nih.gov/news/pr/sep2001/od-05.htm. 
124. WiCell is a non-profit supporting organization of the University of Madison to 
advance the science of stem cells.  See WiCell and The National Stem Cell Bank Home Page, 
http://www.wicell.org (last visited Sept. 2, 2007). 
125. Carl Gulbrandsen, Stem-Cell Patent Holder’s View of the California Challenge, 
WIS. TECH. NETWORK (Nov. 16, 2004), http://wistechnology.com/printarticle.php?id=1352. 
126. Donley, supra note 121. 
127. Id. 
128. Id. 
129. See Letter from Foundation for Taxpayer and Consumer Rights to USPTO (Mar. 
13, 2001), available at http://www.pubpat.org/assets/files/warfstemcell/806Request.pdf (Sept. 
21, 2006) (requesting reexamination of U.S. Patent No. 6,200,806). 
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G.  The Cost Is More Than Reasonable 
The embryonic stem cells are available for a reasonable fee.  
Scientists at academic institutions can obtain free licenses and a vial of 
embryonic stem cells for $500.130  This fee includes scientific training to 
enable interested researchers to work with the cells effectively.131  This 
fee is not only reasonable but in fact quite affordable.  For example, a 
single vial of murine embryonic stem cells costs $250 at the American 
Type Culture Collection (ATCC).132  This ATCC fee does not include 
any training.133  Also, the same hES cells cost $6,000 when provided by 
ES Cell International, a company located in Singapore.134
Importantly, the fee is reasonable when considering that it would 
take tens of thousands of dollars to create an equivalent cell line 
independently.  The cost of salaries, tissue culture media, sterile culture 
dishes, disposable pipette tips, etc., would exceed $500 in just a day.  
Generating a comparable cell line could take years.  Thus, the cost for 
the cell line is reasonable and affordable for any academic scientists that 
desire to work with these cells.  Licensing costs for commercial entities 
are considerably higher.135  But these fees are not burdensome to 
companies, and “it would be unrealistic (and inequitable) for a company 
to obtain the cells for a simple licensing fee.”136  However, the fact that 
commercial entities have to invest several thousand dollars before they 
can utilize the patented technology should not render the patent invalid. 
H.  California v. Wisconsin? 
California proclaims that “[b]y nearly any measure, California is the 
national leader in innovation.”137  Further, “California is responsible for 
one in four patents, attracts half of all venture capital and provides 20 
percent of [all] technology jobs in the United States.  From [its] world-
130. Pollack, supra note 42, at C2. 
  131   See WiCell Research Institute – Unlocking the Potential of Human Embryonic 
Stem Cells, http://www.wicell.org/index.php?option=com_frontpage&Itemid=102 (last visited 
Jan. 11, 2008).   
132. ATCC:  Cell Biology Collection, http://www.atcc.org/common/catalog/numSearch/ 
numResults.cfm?atccNum=SCRC-1029 (last visited Aug. 31, 2007). 
133. See Pollack, supra note 42. 
134. ESI – Stem Cell Products – Order hES, http://www.escellinternational.com/stem 
cellprod/ordercells.htm (last visited Aug. 31, 2007). 
135. $75,000 to $400,000.  Pollack, supra note 38. 
136. Noonan, supra note 109. 
137. Governor Arnold Schwarzenegger, State of the State Address (Jan. 9, 2007), 
available at http://gov.ca.gov/sots/research_innovation.html (last visited Jan. 9, 2007). 
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leading stem cell research initiative to renewable energy and alternative 
fuels, California is the birthplace of innovation.”138  It has “the world’s 
largest concentration of biotechnology companies” and because of its 
commitment to stem cell research, it “has other countries treating the 
state like it is its own nation.”139
There can be no doubt that the numerous outstanding scientists at 
California’s universities as well as in industry form a highly productive 
network.  To support research development and maintain California’s 
“world-leading” position in the scientific arena, California voters 
approved a funding initiative for stem cell research.140  The state is 
proposing a budget of $300 million per year over the next ten years in 
California, which exceeds the NIH’s annual spending for the entire 
nation tenfold.141
The geographical location of the adverse institutions may not be 
coincidental to the pending reexamination.  It has been speculated that 
the challenge is “politically and financially motivated”142 and would not 
have been brought forward had the patent been owned by a California 
institution.  It is conceivable that, had a California institution owned the 
stem cell patents, the validity of the patents would not have been 
questioned. 
In 2004, after the Bush administration had announced its restrictions 
on stem cell research,143 California amended its constitution with the 
California Stem Cell Research and Cures Initiative.144  This amendment 
renders stem cell research a constitutional right in the state of 
California.145  Further, three billion dollars over a period of ten years 
will be made available to fund and provide infrastructure for stem cell 
138. Id. 
139. Terri Somers, Stem Cell Research no Dream for California, SignOnSanDiego 
(2006), http://www.signonsandiego.com/news/business/biotech/20061219-9999-1z1n19stem. 
html. 
140. American Association for the Advancement of Science Policy Brief: Stem Cell 
Research, Stem Cells in the States, available at http://www.aaas.org/spp/cstc/briefs/stemcells 
(last visited Aug. 31, 2007). 
141. The NIH spent $29 million in 2003 for stem cell research in the entire nation.  
Gulbrandsen, supra note 125. 
142. Pollack, supra note 2. 
143. President Discusses Stem Cell Research, The White House, Aug. 9, 2001, 
available at http://www.whitehouse.gov/news/releases/2001/08/20010809-2.html (last visited 
Aug. 31, 2007). 
144. Proposition 71 was codified as CAL. CONST. art. XXXV.  California Stem Cell 
Research and Cures Initiative, Prop. 71, 2004 Cal. Text of Proposed Laws, available at 
http://www.cirm.ca.gov/pdf/prop71.pdf. 
145. Id. 
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research.146  This outstanding commitment to the advancement of 
science is unique in terms of magnitude and structure.  California is the 
“first state to publicly fund embryonic stem cell research.”147
It is thus not surprising that California has a strong interest in the 
availability of stem cell technology.  However, while this strong interest 
is understandable and even honorable, the validity of a patent is not 
dependent on state interests.  The FTCR alleges that the “patents could 
impede th[e] state’s $3 billion stem cell research program.”148  The 
opposite is true, however, because the patents make many aspects of 
this program possible.  Without the patents, the technology would not 
be in the hands of scientists outside of Geron and the Thomson 
laboratory.  Instead, the technology would be a strictly guarded trade 
secret in the hands of Geron who paid for research, and neither 
academia nor industry would have access to it.  Surely, scientists would 
be free to try to generate their own stem cells in the absence of a patent.  
However, before Dr. Thomson’s success, scientists have failed for 
decades to do so.149  Thus, the patents under reexamination make many 
aspects of human stem cell research possible, rather than hindering it. 
I.  Scientists Are Not Moving Abroad to Conduct Their Research 
Opponents to the stem cell patents have argued that scientists 
interested in working in the stem cell field will flee to other countries.150  
While this argument sounds plausible, it has not been corroborated by 
any sound statistical analysis. 
Quite the opposite is true.  There are over 5,000 federally funded 
current or past stem cell-related research projects in the United 
States.151  Furthermore, there are numerous private and public 
companies, not included in this number, that have “taken a good look at 
stem-cell research.”152  In fact, the stem cell research “field is cluttered 
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with companies.”153  Thus, it can hardly be said that the stem cell patents 
force U.S. research endeavors and stem cell scientists abroad.   
There may be several reasons why U.S. stem cell scientists are 
unlikely to go abroad to conduct their research.  The most obvious one 
is that individuals are more likely to switch their research focus than 
leave their country.  It is a great personal commitment and requires 
great courage to leave behind your home and endeavor into the 
unknown.  Many are not willing to adapt into foreign cultures, learn new 
languages, and leave their roots, just to work in a particular area of 
science.  Second, foreign countries have granted several stem cell 
patents.154  Further, some countries do not permit any stem cell 
research.155  Thus, U.S. scientists are unlikely to move their operations 
abroad because the technology is either patented or prohibited.  Third, 
it is not clear if U.S. scientists’ work abroad will be favorably reviewed 
in the United States.  In other words, scientists that are hoping to 
establish themselves in the scientific community and move up within a 
U.S. institution may not be able to accomplish this goal with research 
conducted abroad.  Finally, not all countries that would provide for 
equivalent research facilities permit unbridled embryonic stem cell 
research.156  Thus, the argument that the WARF patents drive U.S. 
scientists to move abroad is unlikely to be meaningful.  While there 
might be individual examples, there is no empirical evidence to support 
this argument and there is not likely to be any in the future.  It might be 
added that even if there was “stem cell off shoring,” it is due to “the 
2001 order by President Bush that restricts federal funding here to 
research on a small number of embryonic stem cell lines.”157
CONCLUSION 
The stem cell patents currently under reexamination by the USPTO 
should be upheld.  WARF’s patents are not obvious in light of the newly 
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cited prior art.  In addition, in times where embryonic research is largely 
dependent on private investors, it is especially important to provide for 
reliable protection of intellectual property.  WARF has shared the 
patented technology extensively with the scientific community and will 
continue to do so.  The fact that commercial entities cannot use the 
patented technologies to maximize their company’s wealth is not 
sufficient to hold the patents invalid. 
Importantly, the patent system ought to provide a sense of stability 
that withstands any political winds.  It is currently challenging for 
competitors to design around the stem cell patents due to the 
restrictions on the generation of new lines.  However, patents should be 
inert against any changes in the political climate.  Otherwise, a patent’s 
term would be effectively reduced to the term of government. 
Patents ensure that the protected technology is used to its fullest.  
Scientific research is moved by “trends” that temporarily make a 
technology “de joure” popular for use by researchers in different 
fields.158  Once the next trend comes along, all interest is focused on this 
new technology.  The investment in a patent assures that a technique, if 
it is promising, will be developed and exploited to its fullest.  Stem cell 
research bears enormous promise.  This technology must be protected 
to ensure investment of time, money, and effort to ensure its 
development to the fullest possible benefit to mankind. 
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